Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels.

The Journal of general physiology - 1 Oct 2018

Yau Michael C, Kim Robin Y, Wang Caroline K, Li Jingru, Ammar Tarek, Yang Runying Y, Pless Stephan A, Kurata Harley T

Abstract excerpt

Retigabine is an antiepileptic drug and the first voltage-gated potassium (Kv) channel opener to be approved for human therapeutic use. Retigabine is thought to interact with a conserved Trp side chain in the pore of KCNQ2-5 (Kv7.2-7.5) channels, causing a pronounced hyperpolarizing shift in the voltage dependence of activation. In this study, we investigate the functional stoichiometry of retigabine actions by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KCNQ2 gene

Share to KCNQ3 gene

Share to KCNQ3 Potassium Channel

Share to Mutation

Share to Phenylenediamines

Share to Xenopus laevis

Source

Open in PubMed Open full text

Identifiers

PMID: 30166314
DOI: 10.1085/jgp.201812013
PMCID: PMC6168243

Genes

KCNQ3
KCNQ2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels.PMID 30166314Read ↗

Four drug-sensitive subunits are required for maximal effect of a voltage sensor-targeted KCNQ opener.Semantic proximity Read ↗

Sequence determinants of subtype-specific actions of KCNQ channel openers.Semantic proximity Read ↗

Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.Semantic proximity Read ↗

Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filterSemantic proximity Read ↗

Retigabine and gabapentin restore channel function and neuronal firing of an epilepsy-associated dominant-negative <i>KCNQ5</i> variantSemantic proximity Read ↗

Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.Semantic proximity Read ↗

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.Semantic proximity Read ↗

Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.Semantic proximity Read ↗

Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs.Semantic proximity Read ↗

Site and Mechanism of ML252 Inhibition of Kv7 Voltage-Gated Potassium Channels.Semantic proximity Read ↗

XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits.Semantic proximity Read ↗

Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.